From 1 September 2026, the prescriber accreditation requirement for hepatitis B medicines under the PBS Section 100 (s100) Highly Specialised Drugs Program will be removed. As a result, all medical and authorised nurse practitioners will be able to prescribe hepatitis B antiviral treatment without additional specialist accreditation. ASHM is currently updating its website, education and resources to reflect this change.

Find out more

Back

National Hepatitis C Testing Policy

First published:

July 2025

Last published:

July 2025

Overview

This Testing Policy has been developed as a concise source of standardised, currently available information to inform those involved in ordering and performing hepatitis C testing. This Policy is not a set of clinical guidelines and it should not be used as a guide for the clinical management of hepatitis C infection.

This Policy was written by the National Hepatitis C Testing Policy Expert Reference Committee, funded by the Australian Government Department of Health. The review process was coordinated by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).

The views expressed in this Policy are not necessarily those of the Commonwealth Government of Australia. The Commonwealth, the Blood Borne Viruses and Sexually Transmissible Infections Standing Committee (BBVSS) of the Australian Health Protection Principal Committee (AHPPC) do not accept any liability for any injury, illness, damage or loss incurred by any person arising from the use of or reliance on the information or advice that is provided in this Testing Policy.

The National Hepatitis C Testing Policy has been endorsed by the Blood Borne Viruses and Sexually Transmissible Infections Committee, effective 22 October 2020. New changes uploaded on 5 June 2025 are in the process of PHLN and BBVSS endorsement.